Tag Archives: Travis Steed

Dexcom (DXCM) Received its Third Buy in a Row

After Oppenheimer and Canaccord Genuity gave Dexcom (NASDAQ: DXCM) a Buy rating last month, the company received another Buy, this time from Merrill Lynch. Analyst Travis Steed reiterated a Buy rating on Dexcom yesterday and set a price target of

Merrill Lynch Believes Dexcom (NASDAQ: DXCM) Won’t Stop Here

In a report released today, Travis Steed from Merrill Lynch maintained a Buy rating on Dexcom (NASDAQ: DXCM), with a price target of $127. The company’s shares opened today at $119.40, close to its 52-week high of $123.48. Steed has

Analysts Offer Insights on Healthcare Companies: Wright Medical Group (NASDAQ: WMGI) and Adaptimmune Therapeutics (NASDAQ: ADAP)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Wright Medical Group (NASDAQ: WMGI) and Adaptimmune Therapeutics (NASDAQ: ADAP) with bullish sentiments. Wright Medical Group (NASDAQ: WMGI) Merrill Lynch analyst Travis

AxoGen Receives a Buy from Cantor Fitzgerald

Cantor Fitzgerald analyst Travis Steed reiterated a Buy rating on AxoGen (NASDAQ: AXGN) today. The company’s shares closed on Friday at $15.55. According to TipRanks.com, Steed is a 3-star analyst with an average return of 6.7% and a 54.5% success

Intuitive Surgical Receives a Hold from Cantor Fitzgerald

In a report released yesterday, Travis Steed from Cantor Fitzgerald maintained a Hold rating on Intuitive Surgical (NASDAQ: ISRG), with a price target of $1050. The company’s shares closed yesterday at $971.73, close to its 52-week high of $974.66. Steed

Viewray Receives a Buy from Cantor Fitzgerald

In a report issued on June 29, Travis Steed from Cantor Fitzgerald initiated coverage with a Buy rating on Viewray (NASDAQ: VRAY) and a price target of $10. The company’s shares opened today at $6.49. According to TipRanks.com, Steed is